Therapeutic developments in pancreatic cancer: current and future perspectives

…, J Kleeff, P Michl, E Costello, W Greenhalf… - Nature reviews …, 2018 - nature.com
The overall 5-year survival for pancreatic cancer has changed little over the past few
decades, and pancreatic cancer is predicted to be the second leading cause of cancer-related …

Early detection of pancreatic cancer

…, MG Keane, SJ Pandol, D Li, W Greenhalf… - The lancet …, 2020 - thelancet.com
Pancreatic ductal adenocarcinoma is most frequently detected at an advanced stage. Such
late detection restricts treatment options and contributes to a dismal 5-year survival rate of 3–…

New biomarkers and targets in pancreatic cancer and their application to treatment

E Costello, W Greenhalf, JP Neoptolemos - … reviews Gastroenterology & …, 2012 - nature.com
Late diagnosis of pancreatic ductal adenocarcinoma (pancreatic cancer) and the limited
response to current treatments results in an exceptionally poor prognosis. Advances in our …

[PDF][PDF] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses

…, J Dunning, T Fletcher, CA Green, W Greenhalf… - Cell, 2022 - cell.com
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529
was announced, containing far more mutations in Spike (S) than previously reported …

[HTML][HTML] Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP …

…, R Hendry, J Scott-Brown, W Greenhalf… - The Lancet …, 2021 - thelancet.com
Background Microbiological characterisation of co-infections and secondary infections in
patients with COVID-19 is lacking, and antimicrobial use is high. We aimed to describe …

Clinical and genetic characteristics of hereditary pancreatitis in Europe

N Howes, MM Lerch, W Greenhalf, DD Stocken… - Clinical …, 2004 - Elsevier
Background & Aims: Hereditary pancreatitis is an autosomal dominant disease that is
mostly caused by cationic trypsinogen (PRSS1) gene mutations. The aim was to determine …

[HTML][HTML] Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study

…, S Clohisey, R Hendry, W Greenhalf… - The Lancet …, 2021 - thelancet.com
Background Prognostic models to predict the risk of clinical deterioration in acute COVID-19
cases are urgently required to inform clinical management decisions. Methods We …

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an …

…, W Steward, A Anthoney, W Greenhalf… - The Lancet …, 2014 - thelancet.com
Background We aimed to assess the efficacy and safety of sequential or simultaneous
telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally …

[HTML][HTML] Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective …

…, S Clohisey, R Hendry, J Scott-Brown, W Greenhalf… - The Lancet, 2021 - thelancet.com
Background COVID-19 is a multisystem disease and patients who survive might have in-hospital
complications. These complications are likely to have important short-term and long-…

Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis

…, M Johnstone, TB Gardner, A Gelrud, W Greenhalf… - Nature …, 2012 - nature.com
Pancreatitis is a complex, progressively destructive inflammatory disorder. Alcohol was long
thought to be the primary causative agent, but genetic contributions have been of interest …